Valuation: Physiomics Plc

Capitalization 2.49M 3.34M 2.88M 2.64M 4.6M 323M 4.71M 31.44M 12.24M 152M 12.53M 12.26M 531M P/E ratio 2026 *
-5.5x
P/E ratio 2027 * -
Enterprise value 2.23M 2.98M 2.57M 2.36M 4.1M 289M 4.21M 28.08M 10.94M 136M 11.19M 10.95M 475M EV / Sales 2026 *
2.23x
EV / Sales 2027 * -
Free-Float
77.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Physiomics Plc

1 day+4.91%
1 week-3.83%
Current month+15.40%
1 month+21.47%
3 months+15.40%
6 months+49.87%
Current year+102.46%
1 week 0.55
Extreme 0.55
0.6
1 month 0.45
Extreme 0.45
0.67
Current year 0.25
Extreme 0.2525
0.8
1 year 0.25
Extreme 0.2525
0.8
3 years 0.25
Extreme 0.2525
3.19
5 years 0.25
Extreme 0.2525
7.94
10 years 0.25
Extreme 0.2525
32
Manager TitleAgeSince
Chief Executive Officer - 2024-01-21
Director of Finance/CFO 52 -
Corporate Officer/Principal - 2021-08-30
Director TitleAgeSince
Chairman 53 2026-04-28
Director/Board Member - 2026-04-28
Director/Board Member - 2026-04-28
Change 5d. change 1-year change 3-years change Capi.($)
+4.91%-3.83%+37.38%-78.63% 3.34M
-1.68%-3.25%-21.72%+12.31% 121B
-1.10%-0.59%+0.88%+22.95% 42.06B
+5.42%+0.54%-55.75%-32.92% 38.14B
-2.07%-3.56%-42.67%-23.46% 19.15B
-4.36%+10.44%-60.71%-41.80% 17.16B
+1.12%+12.04%-19.16%+52.85% 13.58B
-3.67%-4.51%-28.07%-6.47% 12.74B
-1.08%+2.78%-52.82%-43.98% 8.09B
+2.53%-0.17%+125.96%+61.83% 5.35B
Average +0.38%+0.64%-11.67%-7.73% 27.77B
Weighted average by Cap. +1.08%+0.40%-25.05%+2.33%

Financials

2026 *2027 *
Net sales 1M 1.34M 1.16M 1.06M 1.84M 130M 1.89M 12.61M 4.91M 61.05M 5.03M 4.92M 213M -
Net income -314K -421K -363K -332K -579K -40.72M -593K -3.96M -1.54M -19.17M -1.58M -1.54M -66.94M -
Net Debt -266K -356K -307K -282K -490K -34.49M -503K -3.35M -1.31M -16.24M -1.34M -1.31M -56.7M -
Logo Physiomics Plc
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Employees
10
Date Price Change Volume
26-05-20 0.5770 p +4.91% 500,250
26-05-19 0.5500 p 0.00% 2,624,058
26-05-18 0.5500 p -4.35% 4,624,201
26-05-15 0.5750 p -2.54% 1,164,600
26-05-14 0.5900 p -1.67% 2,801,077

Annual profits - Rate of surprise